Get the Stockscreener App
6.59
5.35%
-0.44
Precision Biosciences Inc stock is traded at $6.59, with a volume of 75,300.
It is down -5.35% in the last 24 hours and up +69.74% over the past month.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
See More
Previous Close:
$7.03
Open:
$6.95
24h Volume:
75,300
Relative Volume:
0.29
Market Cap:
$162.95M
Revenue:
$34.26M
Net Income/Loss:
$-46.61M
P/E Ratio:
-1.2721
EPS:
-5.1806
Net Cash Flow:
$-62.01M
1W Performance:
+17.35%
1M Performance:
+69.74%
6M Performance:
+39.21%
1Y Performance:
+32.81%
1-Day Range:
$6.50
$6.95
1-Week Range:
$5.40
$7.59
52-Week Range:
$3.53
$8.82
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
6.59 | 173.83M | 34.26M | -46.61M | -62.01M | -5.1806 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.64 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.21 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.13 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.94 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.26 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
Precision BioSciences, Inc. (DTIL) Shareholder/Analyst CallSlideshow (NASDAQ:DTIL) 2026-03-18 - Seeking Alpha
Jones Trading reiterates Precision BioSciences stock rating on DMD trial design - Investing.com
Precision BioSciences Announces PBGENE-DMD Investor Update and Highlights ARCUS Gene Editing Platform – March 2026 - Minichart
Precision BioSciences Highlights PBGENE-DMD Program and Trial - TipRanks
Quarterly Risk: How volatile is Precision BioSciences Inc stockEarnings Overview Report & Daily Stock Trend Watchlist - baoquankhu1.vn
Precision BioSciences (DTIL) surpasses Q4 earnings and revenue estimates - MSN
Precision BioSciences (DTIL) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Precision BioSciences Stock (ISIN: US74019P1084) Surges on Q4 Profit Turnaround Amid Analyst Upgrade - AD HOC NEWS
Precision BioSciences (NASDAQ:DTIL) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Precision BioSciences (DTIL) Q4 Profit Of US$19.2m Challenges Ongoing Loss Narrative - simplywall.st
Precision BioSciences Inc buy Jefferies Financial Group Inc. - sharewise.com
DTIL SEC FilingsPrecision Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Jefferies cuts Precision BioSciences stock price target on valuation - Investing.com
Precision BioSciences Advances PBGENE-DMD Trial, Putting New Focus on Duchenne Gene Therapy - TipRanks
Jefferies Maintains Buy for Precision BioSciences (DTIL) March 13, 2026 - Meyka
Precision BioSciences (NASDAQ:DTIL) Trading Up 12.1%Here's Why - MarketBeat
Precision BioSciences (DTIL) Swings to $1.05 EPS in Q4, Reversing $2.22 Year-Ago Loss - AlphaStreet
Precision BioSciences (DTIL) Exceeds Expectations for Q4 Earnings and Revenue - Bitget
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Bus - pharmiweb.com
Precision BioSciences presents preclinical data on DMD therapy By Investing.com - Investing.com Nigeria
Precision BioSciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Precision BioSciences (DTIL) Surpasses Q4 Revenue Expectations - GuruFocus
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Surges After Strong Q4 Earnings Bea - GuruFocus
Precision BioSciences Q4 2025 Earnings: $20.1M Profit on $34.2M RevenueNews and Statistics - IndexBox
Precision Biosciences 2025 10-K: Revenue $34.3M, GAAP net loss $(45.7M) - TradingView
Precision BioSciences (NASDAQ: DTIL) turns Q4 profit and extends cash runway to 2028 - Stock Titan
Precision BioSciences: Q4 Earnings Snapshot - Barchart
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update - Yahoo! Finance Canada
Precision BioSciences receives patent allowances for hepatitis B program By Investing.com - Investing.com Canada
Precision BioSciences (DTIL) Secures Key Patent Allowances for P - GuruFocus
Precision BioSciences receives patent allowances for hepatitis B program - Investing.com Australia
Precision BioSciences, Inc. Receives U.S. Patent Allowances Covering PBGENE-HBV Program - marketscreener.com
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program - BioSpace
Precision BioSciences receives U.S. patent allowances covering the PBGENE-HBV program - marketscreener.com
Patent nod through 2044 backs hepatitis B gene edit program - Stock Titan
H.C. Wainwright Sticks to Its Buy Rating for Precision BioSciences (DTIL) - The Globe and Mail
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026 - BioSpace
Precision BioSciences Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Precision BioSciences (DTIL) Presents Promising Preclinical Data for DMD Therapy - GuruFocus
Precision BioSciences presents preclinical data on DMD therapy - Investing.com
One-time gene edit keeps dystrophin flowing 9 months in DMD mice - Stock Titan
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 - BioSpace
Precision BioSciences to Report Q4 and Fiscal Year 2025 Results - National Today
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event - BioSpace
Precision BioSciences Says PBGENE-DMD Receives FDA Fast Track Designation - marketscreener.com
Precision BioSciences stock jumps on FDA Fast Track status By Investing.com - Investing.com Canada
FDA Grants Fast Track Status to Precision BioSciences' (DTIL) PB - GuruFocus
FDA Fast Tracks experimental Duchenne muscular dystrophy therapy - Stock Titan
Forecast Cut: Is Precision BioSciences Inc gaining market shareWeekly Trade Recap & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Earnings Beat: Is Precision BioSciences Inc stock trending bullishPortfolio Update Summary & Real-Time Volume Triggers - baoquankhu1.vn
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precision Biosciences Inc Stock (DTIL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Amoroso Michael | President and CEO |
Feb 18 '26 |
Sale |
3.84 |
20,559 |
78,947 |
243,392 |
| Kelly John Alexander | Chief Financial Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
27,584 |
0 |
134,032 |
| Kelly John Alexander | Chief Financial Officer |
Feb 18 '26 |
Sale |
3.84 |
8,149 |
31,292 |
125,883 |
| Scimeca Dario | General Counsel and Secretary |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
61,382 |
| Scimeca Dario | General Counsel and Secretary |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
56,457 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
126,851 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
121,926 |
0.01%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):